TRAWNasdaqPharmaceutical PreparationsUS GAAP · USD

Traws Pharma, Inc.

Traws Pharma, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing antiviral and oncology product candidates. Its pipeline includes TRX01 (ratutrelvir), a SARS-CoV-2 main protease inhibitor, and tivoxavir marboxil, along with other in-licensed or acquired drug programs.

Kysy yhtiöstä
Liikevaihto2,8milj. USD
+1 134,5 %v/v
Liikevoitto (EBIT)−17,9milj. USD
+87,4 %v/v
EBIT-marginaali−640,7%
+62 356,7 %-yks.v/v
Nettotulos9,2milj. USD
+105,5 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−150−100−50050milj. USD2020: 0,23 milj. USD2020: EBIT −25 milj. USD20202021: 0,23 milj. USD2021: EBIT −16 milj. USD20212022: 0,23 milj. USD2022: EBIT −20 milj. USD20222023: 0,23 milj. USD2023: EBIT −20 milj. USD20232024: 0,23 milj. USD2024: EBIT −142 milj. USD20242025: 2,8 milj. USD2025: EBIT −18 milj. USD20252,8−18
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Antiviral drug candidates70 %

Development-stage antiviral programs targeting viral replication and infection.

Oncology programs20 %

Preclinical or clinical oncology assets pursued through partnerships or internal development.

Licensing revenue10 %

Revenue from collaboration and license agreements tied to deferred or milestone-based recognition.

Asiakkaat

Traws Pharma does not sell commercial medicines directly today; its economic counterparties are primarily pharmaceutical and biotechnology partners, regulators, and clinical trial participants. If approved, its products would be marketed to healthcare providers and patients through partners or an internal commercial organization. The company’s current business model depends on licensing, collaboration, and development funding rather than end-market product sales.

Pharmaceutical and biotechnology partners

License or collaborate on assets for funding, development, and eventual commercialization.

Clinical trial ecosystem

Investigators, sites, and participants used to generate safety and efficacy data.

Regulatory agencies

FDA and foreign regulators that review protocols, data, and approvals.

Future healthcare providers and patients

Would buy approved antiviral or oncology therapies through the healthcare system.

Strategia

The company’s strategy is to advance its antiviral and oncology pipeline through clinical development, regulatory progress, and selective partnering. It also seeks external capital and collaboration structures to fund development and, if approved, to support commercialization without building a large standalone sales force too early.

Advance clinical programsLyhyt aikaväli

Clinical proof-of-concept is the main value driver for a development-stage biotech.

Secure funding and partnershipsLyhyt aikaväli

The company needs external capital and collaborators to sustain development.

Build commercialization optionalityKeskipitkä aikaväli

Approved products will require a route to market, either internal or partnered.

Maantiede

Traws Pharma is headquartered in the United States and conducts its development and regulatory activities primarily from the U.S. Its reported clinical work also includes Australia, where one of its Phase 1 studies was run, and it may seek commercialization through partners in the United States and other territories. Geography matters because the company’s approvals, trial execution, and funding access depend on U.S. and foreign regulatory environments.

Riskit

Traws Pharma faces the classic risks of a clinical-stage biotech: uncertain trial outcomes, regulatory approval risk, and dependence on external financing. Its disclosures also highlight government shutdown and budget-related disruptions, which can delay FDA and SEC actions and complicate capital raising. If it cannot secure funding or partnerships, development and commercialization plans could be materially impaired.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Financing and going-concern risk1Government shutdown and budget disruption2Regulatory approval risk3
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Financing and going-concern riskVaikutus: KriittinenTodennäköisyys: Korkea

    The company requires substantial additional capital to fund operations and trials.

    KohdistuuEquityDebtATMStrategic financing
  2. Government shutdown and budget disruptionVaikutus: KorkeaTodennäköisyys: Korkea

    FDA, SEC, and other agencies may delay reviews and filings during shutdowns.

    Kohdistuu: Regulatory submissions and capital raising

  3. Regulatory approval riskVaikutus: KorkeaTodennäköisyys: Matala

    Drug candidates must satisfy FDA and other regulators before commercialization.

    KohdistuuTrial protocolsLabelingApproval timing
  4. Clinical development failure or delayVaikutus: Korkea

    Pipeline value depends on successful trial design, enrollment, and efficacy/safety results.

    Kohdistuu: TRX01 and tivoxavir marboxil programs

  5. Partnering and commercialization riskVaikutus: Keskitaso

    The company lacks a full commercial organization and may rely on third parties.

    KohdistuuLicensingCo-promotionMarket access

Kirjanpito

Harkinnanvaraiset erät
Revenue recognition and deferred revenue

License/collaboration revenue may be recognized upon termination, milestones, or performance events.

Vaikutus: Can create lumpy quarterly revenue

Fair value of warrant liability

Revaluation of warrants can generate non-cash gains or losses.

Vaikutus: Affects reported net income without changing cash flow

Acquired in-process research and development

Acquired programs with no alternative future use may be expensed immediately.

Vaikutus: Can cause large one-time operating expense charges

Accrued expenses and clinical trial estimates

Trial and vendor costs are estimated before invoices are finalized.

Vaikutus: Affects operating expense timing and comparability

Contingent value rights

Future obligations may depend on development or transaction outcomes.

Vaikutus: Requires judgment in liability measurement

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Terns Pharmaceuticals, Inc.

Pharmaceutical Preparations

Trevi Therapeutics, Inc.

TRVI · Pharmaceutical Preparations

Voyager Therapeutics, Inc.

VYGR · Biological Products, (No Diagnostic Substances)

Kairos Pharma, LTD.

KAPA · Pharmaceutical Preparations

Janux Therapeutics, Inc.

JANX · Pharmaceutical Preparations

MacroGenics, Inc

MGNX · Pharmaceutical Preparations

Päivitetty: 24.9.2026